Association between smoking during radiotherapy and prognosis in head and neck cancer: A follow-up study

Background. The study objective was to confirm a previous finding that patients with stage III/IV squamous head and neck cancer (SHNC) who smoke during radiotherapy (RT) experience reduced survival. Methods. An observational cohort study. Patients' smoking status was assessed weekly by question...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck Vol. 24; no. 12; pp. 1031 - 1037
Main Authors: Browman, George P., Mohide, E. Ann, Willan, Andrew, Hodson, Ian, Wong, Gene, Grimard, Laval, MacKenzie, Robert G., El-Sayed, Samy, Dunn, Edward, Farrell, Sylvia
Format: Journal Article
Language:English
Published: New York Wiley Subscription Services, Inc., A Wiley Company 01-12-2002
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. The study objective was to confirm a previous finding that patients with stage III/IV squamous head and neck cancer (SHNC) who smoke during radiotherapy (RT) experience reduced survival. Methods. An observational cohort study. Patients' smoking status was assessed weekly by questionnaire plus blood cotinine. Patients were assessed every 3 to 4 months for survival. Logistic regression and Cox proportional hazards analyses were used to detect the independent contribution of smoking on survival. Results. Of 148 patients, 113 smoked during RT. Blood cotinine and smoking questionnaire responses were highly correlated (Spearman R = .69; p < .0005). Abstainers and very light smokers experienced better survival than light, moderate, and heavy smokers (median, 42 vs 29 months; p = .07). Tumor and nodal status and years smoked were the most important prognostic factors. Smoking during RT was not an independent predictor of survival, but baseline smoking status was (p = .016). Conclusion. Smoking status should be documented in all future trials of RT in SHNC to allow for pooled analyses with sufficient power to address this question. © 2002 Wiley Periodicals, Inc. Head Neck 24: 1031–1037, 2002
Bibliography:istex:0C690B87AD59C0A6DDD21AF24AB50C04B3676F08
ArticleID:HED10168
Presented at the Workshop on the Biological Prevention and Treatment of Head and Neck Cancer, Arlington, Virginia, September, 1994.
an operating grant from the National Cancer Institute of Canada
ark:/67375/WNG-RP73TGZK-4
the Ontario Clinical Oncology Group, Drs. Mark Levine and Kathleen I. Pritchard, Directors
the Supportive Cancer Care Research Unit, Dr. Timothy Whelan, Director
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.10168